Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | NOS3 | P29474 | 2/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | STAT1 | P42224 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12267898 | 0.85 | HPGD (0.50) | HPGDLMNAL3MBTL1MAPTRAB9A | |
| SCHEMBL759442 | 0.84 | HPGD (0.45) | HPGDLMNAL3MBTL1MAPTRAB9A | |
| SCHEMBL18635909 | 0.83 | KMT2A (0.43) | HPGDLMNAL3MBTL1MAPTRAB9A | |
| SCHEMBL463478 | 0.80 | PLK1 (0.58) | HPGDSMN1; SMN2 | |
| SCHEMBL13760252 | 0.79 | PGR (0.36) | HPGDLMNAMAPTKMT2AALDH1A1 | |
| SCHEMBL16501829 | 0.78 | PLK1 (0.47) | HPGDLMNAL3MBTL1KMT2ASMN1; SMN2 | |
| SCHEMBL182327 | 0.78 | CYP2C9 (0.55) | HPGDLMNAL3MBTL1MAPTRAB9A | |
| SCHEMBL9683939 | 0.78 | MAPT (0.50) | HPGDLMNAL3MBTL1MAPTRAB9A | |
| SCHEMBL8005250 | 0.77 | MAPK1 (0.50) | HPGDLMNAL3MBTL1MAPTRAB9A | |
| SCHEMBL8007548 | 0.77 | MEN1 (0.49) | HPGDLMNAMAPTRAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10022456-B2 | Reversibly masked polymers | Arrowhead Pharmaceuticals, Inc. (US) | 2018-07-17 | — | — | US | disclosed |
| EP-2686019-B1 | CONJUGATED MOLECULES COMPRISING A PEPTIDE DERIVED FROM THE CD4 RECEPTOR COUPLED TO A POLYANIONIC POLYPEPTIDE FOR THE TREATMENT OF AIDS | PASTEUR INSTITUT (FR) | 2017-03-01 | — | — | EP | disclosed |
| EP-2249873-B1 | CONJUGATED MOLECULES COMPRISING A PEPTIDE DERIVED FROM THE CD4 RECEPTOR COUPLED TO A POLYANION FOR THE TREATMENT OF AIDS | PASTEUR INSTITUT (FR) | 2016-11-16 | — | — | EP | disclosed |
| US-20150273081-A1 | Reversibly Masked Polymers | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2015-10-01 | — | — | US | disclosed |
| US-9078928-B2 | Conjugated molecules comprising a peptide derived from the CD4 receptor coupled to a polyanionic polypeptide for the treatment of AIDS | INSTITUT PASTEUR (FR) | 2015-07-14 | — | — | US | disclosed |
| US-20140107043-A1 | NEW CONJUGATED MOLECULES COMPRISING A PEPTIDE DERIVED FROM THE CD4 RECEPTOR COUPLED TO A POLYANIONIC POLYPEPTIDE FOR THE TREATMENT OF AIDS | INSTITUT PASTEUR (FR) | 2014-04-17 | — | — | US | disclosed |
| WO-2012050227-A1 | PEPTIDE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | WO | disclosed |
| US-20120094898-A1 | PEPTIDE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| US-8137695-B2 | Transferring interfering RNA sequences into cells via conjugation with physiologically labile bond associated with polyamine and/or polyvinyl ether | Arrowhead Madison Inc. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8017109-B2 | Cellular deivery, random polyacrylate with multiple hydrophobic monomer | ROCHE MADISON INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-7985406-B2 | For cellular delivery; heteropolymer containing amine containing monomer and hydrophobic monomers | ROCHE MADISON INC. (US) | 2011-07-26 | — | — | US | disclosed |
| US-20100286035-A1 | NEUROMEDIN U DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-11 | — | — | US | disclosed |
| US-20100286035-A1 | NEUROMEDIN U DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-11 | — | — | US | disclosed |
| EP-2206721-A1 | NEUROMEDIN U DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-20090023890-A1 | Membrane Active Heteropolymers | Arrowhead Pharmaceuticals, Inc. | 2009-01-22 | — | — | US | disclosed |
| US-20080287630-A1 | Endosomolytic Poly(Acrylate) Polymers | Arrowhead Pharmaceuticals, Inc. | 2008-11-20 | — | — | US | disclosed |
| US-20080287628-A1 | Endosomolytic Poly(Vinyl Ether) Polymers | Arrowhead Madison Inc. | 2008-11-20 | — | — | US | disclosed |
| US-20080281044-A1 | Endosomolytic Modified Poly(Alcohol) and Poly(Amine) Polymers | ROCHE MADISON INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080281041-A1 | Reverse deactivation of membrane active polymers; cell delivery; labile bonding of polyamines, polyvinyl alcohol, polyallylamine or polyoxyethylene glycol | Arrowhead Madison Inc. | 2008-11-13 | — | — | US | disclosed |
| US-20080152661-A1 | Polyconjugates for In Vivo Delivery of Polynucleotides | Arrowhead Pharmaceuticals, Inc. | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107043-A1 | NEW CONJUGATED MOLECULES COMPRISING A PEPTIDE DERIVED FROM THE CD4 RECEPTOR COUPLED TO A POLYANIONIC POLYPEPTIDE FOR THE TREATMENT OF AIDS | CD4, CD40LG, CD40 | HPGD 4406/4885LMNA 4367/4885L3MBTL1 1734/4885 |
| US-20100286035-A1 | NEUROMEDIN U DERIVATIVE | NMUR1, NMUR2, NMBR | HPGD 2129/4885LMNA 1993/4885L3MBTL1 2199/4885 |
| US-20150273081-A1 | Reversibly Masked Polymers | CD47, MSN, EPCAM | HPGD 4344/4885LMNA 1019/4885L3MBTL1 729/4885 |
| US-10022456-B2 | Reversibly masked polymers | CD47, MSN, EPCAM | HPGD 4344/4885LMNA 1019/4885L3MBTL1 729/4885 |
| US-20080152661-A1 | Polyconjugates for In Vivo Delivery of Polynucleotides | PHAX, PCBP1, NCL | HPGD 4617/4885LMNA 334/4885L3MBTL1 803/4885 |
| US-20120094898-A1 | PEPTIDE DERIVATIVE | NPPA, LNPEP, NGLY1 | HPGD 3157/4885LMNA 774/4885L3MBTL1 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.